LMO2抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

The LMO2 antibody is a crucial tool in studying the LIM domain-only 2 (LMO2) protein, a transcription regulator involved in hematopoietic development and oncogenesis. LMO2. part of the LIM-only protein family, contains two LIM domains that mediate protein-protein interactions, facilitating its role in transcriptional complexes. It is essential for normal hematopoiesis, particularly in erythroid and T-cell development.

In cancer research, LMO2 gained prominence due to its oncogenic role in T-cell acute lymphoblastic leukemia (T-ALL), where aberrant expression drives malignant transformation. The LMO2 antibody is widely used in diagnostic pathology to detect LMO2 overexpression in T-ALL and specific lymphoma subtypes, such as germinal center-derived diffuse large B-cell lymphoma (DLBCL). In DLBCL, LMO2 expression correlates with favorable prognosis and serves as a germinal center B-cell marker, aiding subclassification.

The antibody’s utility extends to research on normal and malignant hematopoiesis, helping elucidate mechanisms of transcriptional regulation and signaling pathways. Commercially available clones (e.g., 1A9-1) are validated for immunohistochemistry (IHC), flow cytometry, and Western blotting. Specificity and sensitivity vary between clones, necessitating careful selection based on application. Overall, the LMO2 antibody bridges diagnostic, prognostic, and basic research applications, emphasizing its importance in understanding hematologic malignancies and developmental biology.